I am a 30‑year‑old man, 6'5" tall and 318 lb, with positive anti‑U1 RNP antibodies, modestly elevated CK and rising ESR, and recent muscle weakness; how serious and how common is my mixed connective tissue disease, and what does this mean for my prognosis?

Your Mixed Connective Tissue Disease Appears Mild with a Favorable Prognosis

Based on your positive anti-U1 RNP antibodies, modestly elevated CK (527 U/L), and muscle weakness that has already improved, you likely have a mild form of mixed connective tissue disease (MCTD) with myositis that carries a generally favorable prognosis, particularly given your normal EMG findings and the fact that your symptoms are already improving without treatment.

Understanding Your Diagnosis

What Your Test Results Mean

Your anti-U1 RNP antibodies (titer 1:160, value 86) confirm MCTD. The pattern of your disease is actually reassuring:

• Your CK elevation is modest (527 U/L, just above the upper limit of 430). This is significantly lower than the severe cases described in the literature, where CK levels often exceed 2000 U/L 1, 2
• Your EMG showed normal muscles during testing, which is a very positive sign. Studies show that patients with anti-U1 RNP myositis who lack severe EMG abnormalities tend to have better outcomes 3
• Your muscle weakness is already improving – you can now get up freely without pain, which suggests you may be in the subset of patients who respond well even without aggressive treatment

How Serious Is This?

MCTD with anti-U1 RNP antibodies is generally one of the more favorable autoimmune myositis conditions. Here's the evidence:

Studies consistently show that anti-U1 RNP-associated myositis has:

• Excellent response to corticosteroids – most patients achieve complete remission within 3 weeks on moderate-dose steroids 4
• Low mortality – in the largest studies, no deaths occurred during follow-up periods 1, 4
• High remission rates – significantly better than other forms of immune-mediated myopathy, with 1- and 2-year remission rates substantially higher than conditions like anti-HMGCR or anti-SRP myositis 2
• Stable clinical course when titers remain stable, as yours appear to be 5

The fact that your muscle weakness improved spontaneously (you can now get up without pain) is particularly encouraging and suggests you may be in the subset with the most favorable prognosis 3.

How Rare Is This?

Anti-U1 RNP-positive myositis is uncommon but not extremely rare:

• It represents a distinct subset of inflammatory myositis patients
• In myositis cohorts, anti-U1 RNP antibodies are found in approximately 10-15% of cases 1
• You fit the demographic profile: patients with anti-U1 RNP myositis tend to be younger (average age ~37 years) and have a higher prevalence in Black individuals (60% in one major study) 1

What You Need to Monitor

Critical Organ Screening

Your rheumatologist is appropriately monitoring you, but you need specific screening for:

1. Interstitial Lung Disease (ILD) – This is your most important concern

• 45-56% of anti-U1 RNP patients develop ILD 1, 2
• You need high-resolution chest CT if not already done
• Pulmonary function tests should be performed regularly
• Any unexplained dyspnea warrants immediate evaluation

2. Cardiac Involvement

• Pericarditis occurs in 40% of anti-U1 RNP patients 1
• Your cardiac workup (stress test, 7-day monitor) is appropriate
• The fact that your troponin decreased (9→6 ng/L) and your 12-lead EKG was normal is reassuring
• Continue monitoring for any chest pain or shortness of breath

3. Kidney Disease

• Glomerulonephritis occurs in 25% of anti-U1 RNP patients, but notably only in those who also have anti-Ro52 antibodies 1
• Your eGFR values (87-93) are currently normal
• Regular urinalysis and blood pressure monitoring are essential

4. Arthritis

• 60% of anti-U1 RNP patients develop arthritis 1, 2
• This is more common than in other myositis subtypes
• Report any joint pain or swelling to your rheumatologist

Your G6PD Deficiency

Your G6PD level of 41 (normal 100-400) is significantly low. This is important because:

• Avoid oxidative stress triggers (certain medications, fava beans, infections)
• Some immunosuppressive medications may need dose adjustments
• Inform all healthcare providers about this condition

Treatment Approach

Current Status Assessment

Based on your presentation, you appear to have Grade 1-2 myositis (using standard grading criteria):

• Your CK is elevated but less than 3× upper limit of normal
• Your muscle weakness has improved significantly
• You can perform daily activities without severe limitation

Treatment Recommendations

If your rheumatologist decides treatment is needed (given your rising CK from 371→527 and rising ESR from 2→18):

1. First-line therapy: Prednisone 0.5-1 mg/kg daily 6

   • For your weight (318 lbs = 144 kg), this would be approximately 70-140 mg daily
   • Most anti-U1 RNP patients respond rapidly to moderate doses 4
   • Expect improvement within 3 weeks if treatment is effective

2. Monitoring during treatment:

   • CK, ESR, and CRP should be checked regularly 6
   • Muscle strength assessment at each visit
   • If CK normalizes and symptoms resolve, slow taper over 4-6 weeks

3. If inadequate response (unlikely given your profile):

   • Consider adding immunosuppressants like methotrexate, azathioprine, or mycophenolate mofetil 6
   • IVIG or rituximab are options for refractory cases 2, 7

Important Caveats

Watch for worsening that would require more aggressive treatment:

• If your CK rises above 1500 U/L (3× upper limit)
• If you develop severe weakness limiting self-care activities
• If you develop respiratory muscle weakness or dysphagia
• If cardiac involvement worsens (elevated troponin, new arrhythmias)

Any of these would escalate you to Grade 3 severity requiring prednisone 1 mg/kg or higher, possible hospitalization, and consideration of IVIG or plasmapheresis 6.

Your Specific Concerns Addressed

The Muscle Twitching

This is common in inflammatory myositis and typically improves with treatment. It's not a sign of severe disease.

The "Weird Feeling" When Sitting

This could represent mild proximal muscle involvement but is not concerning given your overall improvement.

Your Rising Inflammatory Markers

• ESR: 2→18 (mild elevation)
• CRP: 3.3→3 (stable, minimal elevation)
• CK: 371→527 (modest elevation)

These trends warrant monitoring but are not in the severe range. The fact that your symptoms improved despite these lab changes suggests your disease may be stabilizing.

Bottom Line

You have a mild form of MCTD with myositis that has an excellent prognosis. The literature consistently shows that patients with anti-U1 RNP antibodies, especially those who respond quickly to treatment (or improve spontaneously as you have), have:

• Low mortality (essentially zero in most studies) 1, 4
• High remission rates 2, 4
• Good functional outcomes 3

Your main risks going forward are:

1. ILD (45-56% risk) – requires regular pulmonary monitoring 1, 2
2. Pericarditis (40% risk) – your cardiac workup is addressing this 1
3. Arthritis (60% risk) – manageable with standard treatments 1, 2

The fact that your rheumatologist is comfortable managing you via telemedicine for your next visit suggests they also view your condition as stable and not immediately concerning. However, ensure you have clear instructions on when to seek urgent evaluation (new shortness of breath, severe weakness, chest pain, or significantly elevated CK).

Your prognosis is favorable, and with appropriate monitoring and treatment if needed, you should expect to maintain good quality of life with minimal long-term disability.